Recomendaciones para el tratamiento farmacológico de la hiperglucemia en la diabetes tipo 2

@article{Torre2011RecomendacionesPE,
  title={Recomendaciones para el tratamiento farmacol{\'o}gico de la hiperglucemia en la diabetes tipo 2},
  author={Edelmiro Men{\'e}ndez Torre and J. Lafita Tejedor and Sara Artola Men{\'e}ndez and Jes{\'u}s Mill{\'a}n N{\'u}{\~n}ez-Cort{\'e}s and Alexandra A. Garc{\'i}a and Manuel Puig Domingo and Jos{\'e} Ram{\'o}n Garc{\'i}a Sol{\'a}ns and Fernando {\'a}lvarez Guisasola and Javier Garc{\'i}a Alegr{\'i}a and Jos{\'e} Javier Mediavilla Bravo and Carlos Miranda Fern{\'a}ndez-Santos and Ram{\'o}n Romero Gonz{\'a}lez},
  journal={Semergen - Medicina De Familia},
  year={2011},
  volume={37},
  pages={74-82}
}
27 Citations
Tratamiento actual de la diabetes mellitus tipo 2
TLDR
La revision abordo la necesidad de modificar estilos de vida, sintetiza algunas caracteristicas farmacologicas en cada grupo, se mostro un novedoso arsenal terapeutico como alternativa de impacto y propuso la combinacion de dos y tres medicamentos hipoglucemiantes.
Control de la diabetes mellitus en población adulta según las características del personal de enfermería de atención primaria de la Comunidad de Madrid: análisis multinivel
TLDR
Son factores de riesgo de tener mal controlada the diabetes mellitus the mayor proporcion of pacientes mayores de 65 anos por enfermera, ser inmigrante y the proporCion ofpacientes sin seguimiento.
...
1
2
3
...

References

SHOWING 1-10 OF 100 REFERENCES
Effect of a multifactorial intervention on mortality in type 2 diabetes
TLDR
En el grupo intervención recibían terapia intensiva teniendo como objetivos las últimas guías de la ADA con un bloqueador del sistema renina angiotensina y una dosis profiláctica con 150mg diarios de AAS.
Defining the Role of Repaglinide in the Management of Type 2 Diabetes Mellitus
  • O. Johansen, K. Birkeland
  • Medicine, Biology
    American journal of cardiovascular drugs : drugs, devices, and other interventions
  • 2007
TLDR
Repaglinide is a compound that can be used in both mono- and combination therapy for the treatment of both fasting and postprandial hyperglycemia in patients with T2DM and is associated with less weight gain than sulphonylureas and the glitazones.
Effect of pioglitazone on metabolic syndrome risk factors: results of double-blind, multicenter, randomized clinical trials*
TLDR
Treatment with pioglitazone as monotherapy or combination therapy led to sustained, positive effects on important components of metabolic syndrome in patients with type 2 diabetes, independent of effects on blood glucose control and, as such, could be translated to potential for reducing the risk of cardiovascular disease.
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.
TLDR
Adjunctive exenatide treatment for > or = 3 years in T2DM patients resulted in sustained improvements in glycemic control, cardiovascular risk factors, and hepatic biomarkers, coupled with progressive weight reduction.
Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control.
  • H. Rodbard, P. Jellinger, S. Schwartz
  • Medicine
    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • 2009
TLDR
An algorithm to assist primary care physicians, endocrinologists, and others in the management of adult, nonpregnant patients with type 2 diabetes mellitus to achieve a hemoglobin A1c of 6.5% or less is presented, with recognition of the need for individualization to minimize the risks of hypoglycemia.
Meglitinide analogues for type 2 diabetes mellitus.
TLDR
There is no evidence available to indicate what effect meglitinides will have on important long-term outcomes, particularly mortality, butMeglitinides may offer an alternative oral hypoglycaemic agent of similar potency to metformin, and may be indicated where side effects of met formin are intolerable or where metform in is contraindicated.
The Effect of Adding Exenatide to a Thiazolidinedione in Suboptimally Controlled Type 2 Diabetes
TLDR
This study compares the glycemic and body weight effects of exenatide versus placebo in patients with type 2 diabetes with suboptimal glycemic control who are receiving a background therapy of TzD or TZD plus metformin.
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.
TLDR
Exenatide was generally well tolerated and reduced HbA(1c) with no weight gain and no increased incidence of hypoglycemia in patients with type 2 diabetes failing to achieve glycemic control with metformin.
...
1
2
3
4
5
...